Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
SAN FRANCISCO, May 07, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in Solid Biosciences, Inc. (NASDAQ:SLDB) of the May 29, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased Solid Biosciences securities pursuant and/or traceable to its January 25, 2018 initial public offering and/or on the open market between January 25, 2018 and March 14, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/SLDB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
Defendants conducted an initial public offering of Solid Biosciences on or about January 25, 2018. In this IPO, the Company sold approximately 7 million shares at $16 per share to investors.
On March 15, 2018, Defendants announced the U.S. Food and Drug Administration placed a clinical hold on the Company’s Phase 1/2 trial assessing its SGT-001 drug in patients with Duchenne muscular dystrophy. This news drove the price of Solid Biosciences shares down $16.99, or about 65%, to close at $9.32.
The Motley Fool later reported that just prior to the IPO, a prominent researcher left its board because of risks associated with the drug delivery method for Solid Biosciences’ SGT-001 drug.
“We’re focused on investors’ losses and Defendants’ disclosures about internal concerns over the safety of the SGT-001 delivery method leading up to- and after- the IPO,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Solid Biosciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
